Core Viewpoint - Solaris Energy Infrastructure, Inc. is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for February 24, and better-than-expected key numbers could lead to a stock price increase, while missing expectations may result in a decline [2]. - The consensus estimate for quarterly earnings is $0.24 per share, reflecting a year-over-year change of +100%, with revenues projected at $164.99 million, up 71.3% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 8.74% over the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Solaris Energy is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -44.92% and a Zacks Rank of 5, suggesting bearish sentiment among analysts [12][13]. Earnings Surprise History - In the last reported quarter, Solaris Energy was expected to post earnings of $0.24 per share but actually delivered $0.32, resulting in a surprise of +33.33% [14]. - Over the past four quarters, the company has exceeded consensus EPS estimates three times [15]. Conclusion - Solaris Energy Infrastructure, Inc. does not currently appear to be a strong candidate for an earnings beat, and investors should consider additional factors when making decisions regarding this stock ahead of its earnings release [18].

Company Overview - Harrow (HROW) is expected to report a year-over-year increase in earnings due to higher revenues for the quarter ended June 2025, with a consensus EPS estimate of $0.00 per share, indicating a +100% change [1][3] - Revenues are projected to be $65.32 million, reflecting a 33.5% increase from the same quarter last year [3] Earnings Expectations - The upcoming earnings report is anticipated to be released on August 11, and the stock may rise if actual results exceed expectations, while a miss could lead to a decline [2] - The consensus EPS estimate has been revised down by 7.89% over the last 30 days, indicating a bearish sentiment among analysts [4] Earnings Surprise Prediction - The Most Accurate Estimate for Harrow is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1,000.01%, which complicates predictions of an earnings beat [12] - Harrow currently holds a Zacks Rank of 3, suggesting a neutral outlook [12] Historical Performance - In the last reported quarter, Harrow was expected to post earnings of $0.02 per share but instead reported a loss of -$0.38, resulting in a surprise of -2,000.00% [13] - Over the past four quarters, Harrow has beaten consensus EPS estimates two times [14] Industry Context - Aclaris Therapeutics (ACRS), another player in the Zacks Medical - Drugs industry, is expected to report a loss of $0.13 per share for the same quarter, indicating a year-over-year change of +13.3% [18] - Aclaris's revenues are expected to be $1.55 million, down 44% from the previous year, with a consensus EPS estimate revised 1.4% higher recently [19]